Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER4 | P35408 | 10/20 | 0.41 |
| ▸ | PTGER2 | P43116 | 7/20 | 0.41 |
| ▸ | PTGER3 | P43115 | 4/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
| ▸ | KAT2B | Q92831 | 2/20 | 0.32 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.31 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22025589 | 0.89 | PTGER4 (0.40) | PTGER4PTGER2PTGER3KCNH2KAT2B | |
| SCHEMBL15586926 | 0.89 | PTGER4 (0.40) | PTGER4PTGER2PTGER3KCNH2KAT2B | |
| SCHEMBL16401236 | 0.81 | PTGER4 (0.41) | PTGER4PTGER2PTGER3KCNH2KAT2B | |
| SCHEMBL15587143 | 0.81 | PTGER4 (0.41) | PTGER4PTGER2PTGER3KCNH2KAT2B | |
| SCHEMBL16819140 | 0.78 | PTGER4 (0.51) | PTGER4PTGER2PTGER3KCNH2KAT2B | |
| SCHEMBL15587107 | 0.78 | PTGER4 (0.51) | PTGER4PTGER2PTGER3KCNH2KAT2B | |
| SCHEMBL18942713 | 0.76 | PTGER4 (0.43) | PTGER4PTGER2PTGER3KCNH2KAT2B | |
| SCHEMBL18943367 | 0.71 | PTGER4 (0.49) | PTGER4PTGER2PTGER3KCNH2 | |
| SCHEMBL16819283 | 0.71 | PTGER4 (0.80) | PTGER4PTGER2PTGER3KCNH2 | |
| SCHEMBL15549891 | 0.71 | PTGER4 (0.80) | PTGER4PTGER2PTGER3KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180170918-A1 | METHODS OF SYNTHESIZING A DIFLUOROLACTAM ANALOG | CAYMAN CHEMICAL CO INC (US) | 2018-06-21 | — | — | US | disclosed |
| US-20180170918-A1 | METHODS OF SYNTHESIZING A DIFLUOROLACTAM ANALOG | CAYMAN CHEMICAL CO INC (US) | 2018-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180170918-A1 | METHODS OF SYNTHESIZING A DIFLUOROLACTAM ANALOG | PTGER4, PTGER1, PTGIR | PTGER4 1/4885PTGER2 9/4885PTGER3 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.